Announcements Trials
Browse Landscape

Phase

Phase 3 5

Status

Completed 5

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Conditions

Colitis, Ulcerative 5

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × etrolizumab × Clear all
NCT02136069 2021-12-03

GARDENIA

Hoffmann-La Roche

Phase 3 Completed
397 enrolled 32 charts

Colitis, Ulcerative

NCT02165215 2021-08-19

LAUREL

Hoffmann-La Roche

Phase 3 Completed
359 enrolled 34 charts

Colitis, Ulcerative

NCT02100696 2021-08-13

HICKORY

Hoffmann-La Roche

Phase 3 Completed
609 enrolled 52 charts

Colitis, Ulcerative

NCT02163759 2021-07-23

HIBISCUS I

Hoffmann-La Roche

Phase 3 Completed
358 enrolled 42 charts

Colitis, Ulcerative

NCT02171429 2021-07-23

HIBISCUS II

Hoffmann-La Roche

Phase 3 Completed
358 enrolled 38 charts

Colitis, Ulcerative

Data powered by HemOnc (CC BY 4.0) Colophon âš¡